ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc.
Your view on CLPT
Overview
What the company does, where it operates, and who runs it.
About ClearPoint Neuro, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Joseph Michael Burnett
- Headquarters
- 120 S. Sierra Avenue, Solana Beach, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Joseph Michael Burnett
- Headquarters
- 120 S. Sierra Avenue, Solana Beach, CA, US
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance.
It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite.
It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco.
The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ClearPoint Neuro, Inc., and the rating behind it. CLPT last traded at $13.72; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ClearPoint Neuro, Inc.. Starting points for ClearPoint Neuro, Inc.: EPS -$1.16, beta 1.27 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ClearPoint Neuro, Inc.. ClearPoint Neuro, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ClearPoint Neuro, Inc.. Trailing twelve-month EPS for ClearPoint Neuro, Inc. stands at -$1.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ClearPoint Neuro, Inc.. ClearPoint Neuro, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ClearPoint Neuro, Inc. valued side by side against its closest peers. ClearPoint Neuro, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ClearPoint Neuro, Inc., and how their positions are changing. At a $411.5M market value, institutional positions materially move ClearPoint Neuro, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ClearPoint Neuro, Inc. executives and directors. Shares of ClearPoint Neuro, Inc. have traded between $9.76 and $30.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ClearPoint Neuro, Inc.. ClearPoint Neuro, Inc. is a $411.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ClearPoint Neuro, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ClearPoint Neuro, Inc.. Coverage tracks ClearPoint Neuro, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.